474658-53-2

Upstream product

• 102-29-4 Resorcinol monoacetate 
• 474658-50-9 3-[1,1-bis(methylethyl)-2-methyl-1-silapropoxy]phenyl acetate 
• 205676-85-3 ethyl 2-{6-[(tert-butoxy)-N-methylcarbonylamino]-2-pyridyl}acetate 
• 205676-84-2 (tert-butoxy)-N-methyl-N-[6-methyl-(2-pyridyl)]carboxamide 
• 90101-22-7 2-(tert-butoxycarbonylamino)-6-picoline 
• 205676-87-5 2-methylamino-6-(2-hydroxyethyl)pyridine 
• 14794-31-1 ethyl 3-(chloroformyl)propionate 
• 1824-81-3 2-Amino-6-methylpyridine 
• 14594-25-3 ethyl 5-bromo-4-oxopentanoate 
• 474658-52-1 [6-(2-{3-[1,1-bis(methylethyl)-2-methyl-1-silapropoxy]phenoxy}ethyl)(2-pyridyl)]methylamine 
• 474658-51-0 3-[1,1-bis(methylethyl)-2-methyl-1-silapropoxy]phenol 
• 205676-86-4 ethyl 2-[6-(methylamino)-2-pyridyl]acetate 

Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of novel potent and selective αvβ3/αvβ5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core

A novel series of potent and selective αvβ 3/αvβ5 dual inhibitors was designed, synthesized, and evaluated against several integrins. These compounds were synthesized through a Mitsunobu reaction between the gua

Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists

The present invention relates to novel substituted benzofurans and benzothiophenes compounds that are antagonists of alpha V (αv) integrins, for example αvβ3 and αvβ5 integrins, their pharmaceutically acceptable